A leading solution in target deconvolution and receptor identification
Retrogenix provides the leading solution for receptor and membrane target deconvolution. We specialise in discovering which human plasma membrane proteins are targeted by antibodies, proteins, small molecules and viruses.
Retrogenix identifies on behalf of its clients:
Target deconvolution is achieved by screening our clients’ molecules for interactions against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Now covering more than 3500 proteins, this represents the majority of known plasma membrane proteins.
Retrogenix has a rich client portfolio, including many global pharmaceutical / drug discovery companies and several notable academic institutions. We give our commercial clients a competitive advantage by identifying high quality, unexploited drug targets, and helping them to improve success rates at all stages of the drug research and development process.
20/11/2014 | Dr Freeth to present on target deconvolution strategies at Antibody Engineering & Therapeutics meeting in California. Dr Jim Freeth will be presenting and exhibiting at the 10th Annual European Antibody Congress in Geneva, Switzerland. The three day meeting will provide... | Read More
Retrogenix will be attending the IBC Antibody Engineering & Therapeutics from the 7th - 11th December in Huntington Beach, California | Find out more
“…"no doubt" that the breakthrough in identifying EPCR was due to the Retrogenix screening tool” | Read more
Professor Thomas Lavstsen, University of Copenhagen